Investigation comes after a August 10, 2026 report concerning Tenax Therapeutics, Inc.; shareholders who suffered losses may have claims to recover them

Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc.

Investors with losses on Tenax Therapeutics, Inc. securities can contact The Law Offices of Howard G. Smith about the Tenax Therapeutics, Inc. investigation to learn about potentially pursuing claims to recover their losses.

Key facts for Tenax Therapeutics, Inc. investors

• Disclosure: August 10, 2026
• Stock drop: $12.06 per share, or 89.77%
• Close after the drop: $1.38 on August 10, 2026

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

"On August 10, 2026, it was reported that Tenax's Phase 3 LEVEL trial of TNX-103 had failed to meet its primary endpoint of improved 6-minute walk distance versus placebo or its key secondary endpoint of improved Kansas City Cardiomyopathy Questionnaire total symptom score, and Tenax Therapeutics, Inc. stock lost 89.77% of its value. Our investigation is focused on whether shareholders had the full story before that report," said Howard G. Smith of The Law Offices of Howard G. Smith.

Next steps for Tenax Therapeutics, Inc. investors

The Law Offices of Howard G. Smith is examining potential claims on behalf of Tenax Therapeutics, Inc. investors. Investors with losses can visit the firm's website, email howardsmith@howardsmithlaw.com, or call (215) 638-4847 to discuss the Tenax Therapeutics, Inc. investigation.

Common questions from Tenax Therapeutics, Inc. investors

Who is eligible? Tenax Therapeutics, Inc. investors who bought securities and lost money may have claims, and can reach out to the firm to learn whether the Tenax Therapeutics, Inc. investigation affects them.

What is a securities fraud investigation? Through the Tenax Therapeutics, Inc. investigation, The Law Offices of Howard G. Smith is reviewing whether the Company or its officers may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces an investigation of Tenax Therapeutics, Inc. by The Law Offices of Howard G. Smith, not a lawsuit. If a securities class action is later filed, Tenax Therapeutics, Inc. investors may be able to seek appointment as lead plaintiff.

Does it cost anything? The Law Offices of Howard G. Smith works on contingency, meaning Tenax Therapeutics, Inc. investors owe no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid solely from a recovery, if achieved, and require court approval.

Whistleblower notice

Individuals with non-public information about Tenax Therapeutics, Inc. should consider their options to help the investigation or take part in the SEC Whistleblower Program. Whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Howard G. Smith at (215) 638-4847 or email howardsmith@howardsmithlaw.com.

About The Law Offices of Howard G. Smith

The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.

Prior results do not guarantee a similar outcome.

Related links

• Tenax Therapeutics, Inc. investigation, The Law Offices of Howard G. Smith
• Tenax Press Release
• Tenax Therapeutics, Inc. SEC filings index, EDGAR
• SEC Whistleblower Program
• The Law Offices of Howard G. Smith

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261030263029/en/